Vitro Biopharma, Inc.

2024 Q2 Form 10-Q Financial Statement

#000149315224022030 Filed on May 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q2

Balance Sheet

Concept 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $1.664M $251.7K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $181.7K $224.5K
Prepaid Expenses $119.4K $122.1K
Receivables $157.1K $47.54K
Other Receivables
Total Short-Term Assets $2.122M $2.644M
YoY Change -19.72%
LONG-TERM ASSETS
Property, Plant & Equipment $228.6K $288.2K
YoY Change -20.66%
Goodwill $3.609M $3.609M
YoY Change 0.0%
Intangibles $633.9K $1.312M
YoY Change -51.67%
Long-Term Investments
YoY Change
Other Assets $8.438K $13.86K
YoY Change -39.12%
Total Long-Term Assets $4.973M $5.512M
YoY Change -9.79%
TOTAL ASSETS
Total Short-Term Assets $2.122M $2.644M
Total Long-Term Assets $4.973M $5.512M
Total Assets $7.095M $8.156M
YoY Change -13.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.180M $917.3K
YoY Change 137.65%
Accrued Expenses $1.551M $958.8K
YoY Change 61.79%
Deferred Revenue
YoY Change
Short-Term Debt $2.911M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.41M $2.851M
YoY Change 264.91%
LONG-TERM LIABILITIES
Long-Term Debt $2.995M $3.226M
YoY Change -7.16%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.246M $4.420M
YoY Change -3.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.41M $2.851M
Total Long-Term Liabilities $4.246M $4.420M
Total Liabilities $14.65M $7.271M
YoY Change 101.5%
SHAREHOLDERS EQUITY
Retained Earnings -$35.76M -$25.32M
YoY Change 41.23%
Common Stock $4.460K $115.4K
YoY Change -96.14%
Preferred Stock
YoY Change
Treasury Stock (at cost) $84.00K $84.00K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity -$7.556M $885.0K
YoY Change
Total Liabilities & Shareholders Equity $7.095M $8.156M
YoY Change -13.01%

Cashflow Statement

Concept 2024 Q2 2023 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 VTRO Writeoff Of Offering Costs
WriteoffOfOfferingCosts
usd
CY2024Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
CY2023Q4 VTRO Convertible Long Term Notes Payable Stock Settled Net
ConvertibleLongTermNotesPayableStockSettledNet
usd
CY2023Q4 VTRO Derivative Warrant Liability
DerivativeWarrantLiability
usd
CY2023Q4 VTRO Note Subscription Payable
NoteSubscriptionPayable
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
VTRO Writeoff Of Offering Costs
WriteoffOfOfferingCosts
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
usd
VTRO Increase Decrease In Prepaid Project Costs
IncreaseDecreaseInPrepaidProjectCosts
usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
VTRO Increase Decrease In Accrued Liabilities Related Party
IncreaseDecreaseInAccruedLiabilitiesRelatedParty
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
VTRO Proceeds From Issuance Of Series Senior Convertible Notes Payable Stock Settled
ProceedsFromIssuanceOfSeriesSeniorConvertibleNotesPayableStockSettled
usd
VTRO Proceeds From Note Subscription Payable
ProceedsFromNoteSubscriptionPayable
usd
VTRO Proceeds From Issuance Of Convertible Notes Payable Stock Settled
ProceedsFromIssuanceOfConvertibleNotesPayableStockSettled
usd
VTRO Proceeds From Issuance Of Series B Convertible Notes Payable Stock Settled
ProceedsFromIssuanceOfSeriesBConvertibleNotesPayableStockSettled
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
VTRO Noncash Or Part Noncash Premium On Issuance Of Series Senior Notes Payable Stock Settled
NoncashOrPartNoncashPremiumOnIssuanceOfSeriesSeniorNotesPayableStockSettled
usd
VTRO Noncash Or Part Noncash Derivativewarrant Liability Series Senior Notes Payable
NoncashOrPartNoncashDerivativewarrantLiabilitySeriesSeniorNotesPayable
usd
VTRO Noncash Or Part Noncash Discount On Derivativewarrant Liability Series Senior Secured Notes Payable
NoncashOrPartNoncashDiscountOnDerivativewarrantLiabilitySeriesSeniorSecuredNotesPayable
usd
VTRO Noncash Or Part Noncash Premium On Issuance Of Series Notes Payable
NoncashOrPartNoncashPremiumOnIssuanceOfSeriesNotesPayable
usd
VTRO Noncash Or Part Noncash Derivativewarrant Liability Series Notes Payable
NoncashOrPartNoncashDerivativewarrantLiabilitySeriesNotesPayable
usd
VTRO Noncash Or Part Noncash Discount On Derivativewarrant Liability Series Notes Payable One
NoncashOrPartNoncashDiscountOnDerivativewarrantLiabilitySeriesNotesPayableOne
usd
VTRO Noncash Or Part Noncash Forgiveness Of Accrued Liabilities Related Party
NoncashOrPartNoncashForgivenessOfAccruedLiabilitiesRelatedParty
usd
VTRO Noncash Or Part Noncash Deferred Offering Costs Recorded As Accounts Payable
NoncashOrPartNoncashDeferredOfferingCostsRecordedAsAccountsPayable
usd
us-gaap Other Income
OtherIncome
usd
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
usd
us-gaap Other Income
OtherIncome
usd
CY2024Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
usd
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
usd
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
usd
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
usd
CY2024Q2 VTRO Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
usd
CY2023Q4 VTRO Convertible Series Senior Secure Short Term Notes Payable
ConvertibleSeriesSeniorSecureShortTermNotesPayable
usd
CY2023Q4 VTRO Convertible Series Senior Secure Short Term Notes Payable Discount
ConvertibleSeriesSeniorSecureShortTermNotesPayableDiscount
usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4460535 shares
CY2024Q2 us-gaap Cash
Cash
1664016 usd
CY2023Q4 us-gaap Cash
Cash
101754 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
157105 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
119671 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
181694 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
170752 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
119401 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
130851 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2656326 usd
CY2024Q2 VTRO Convertible Long Term Notes Payable Stock Settled Net
ConvertibleLongTermNotesPayableStockSettledNet
2431068 usd
CY2024Q2 VTRO Derivative Warrant Liability
DerivativeWarrantLiability
2861775 usd
CY2024Q2 VTRO Note Subscription Payable
NoteSubscriptionPayable
150000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
61832 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
130150 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4850110 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
17123 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
346091 usd
CY2023Q4 VTRO Unsecured Note Payable Related Party Noncurrent
UnsecuredNotePayableRelatedPartyNoncurrent
767288 usd
CY2023Q4 VTRO Unsecured Note Payable Related Party Noncurrent One
UnsecuredNotePayableRelatedPartyNoncurrentOne
1221958 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
200000 usd
CY2023Q4 VTRO Convertible Long Term Notes Payable Stock Settled Net Non Current
ConvertibleLongTermNotesPayableStockSettledNetNonCurrent
340715 usd
CY2023Q4 VTRO Convertible Long Term Notes Payable Stock Settled Net One
ConvertibleLongTermNotesPayableStockSettledNetOne
421018 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
893263 usd
CY2023Q4 VTRO Long Term Accrued Interest Payable
LongTermAccruedInterestPayable
92311 usd
CY2023Q4 VTRO Long Term Accrued Interest Payable Related Party
LongTermAccruedInterestPayableRelatedParty
284747 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4584514 usd
CY2023Q4 us-gaap Liabilities
Liabilities
9434624 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
19230770 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
19230770 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4460535 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4430535 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4430 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27064613 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
84000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28076133 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1091090 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8343534 usd
CY2023Q2 us-gaap Revenues
Revenues
307843 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
62634 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
245209 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1537181 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66447 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1358419 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
2160299 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
56937 usd
CY2024Q2 VTRO Unrealized Gain Loss On Derivatives One
UnrealizedGainLossOnDerivativesOne
-12874 usd
CY2023Q2 VTRO Unrealized Gain Loss On Derivatives One
UnrealizedGainLossOnDerivativesOne
656 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3118919 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1414700 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4460535 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4460535 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4430535 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4430535 shares
us-gaap Revenues
Revenues
997147 usd
us-gaap Revenues
Revenues
651874 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
179364 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
129145 usd
us-gaap Gross Profit
GrossProfit
817783 usd
us-gaap Gross Profit
GrossProfit
522729 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3685447 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2958351 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
295924 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73280 usd
VTRO Writeoff Of Offering Costs
WriteoffOfOfferingCosts
2656962 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5820550 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2508902 usd
us-gaap Interest Expense
InterestExpense
2331928 usd
us-gaap Interest Expense
InterestExpense
96630 usd
VTRO Unrealized Gain Loss On Derivatives One
UnrealizedGainLossOnDerivativesOne
464373 usd
VTRO Unrealized Gain Loss On Derivatives One
UnrealizedGainLossOnDerivativesOne
707 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7688105 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2604825 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4457898 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4457898 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4430535 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4430535 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2835840 usd
CY2023Q1 VTRO Adjustments To Additional Paid In Capital Forgiven Accrued Payables Related Party
AdjustmentsToAdditionalPaidInCapitalForgivenAccruedPayablesRelatedParty
137953 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
122562 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1190125 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1906230 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
393510 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1414700 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
450000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
384484 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4569186 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4825792 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4825792 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
388367 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3118919 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-7556344 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-7556344 usd
us-gaap Net Income Loss
NetIncomeLoss
-7688105 usd
us-gaap Net Income Loss
NetIncomeLoss
-2604825 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
464374 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
707 usd
us-gaap Depreciation
Depreciation
91785 usd
us-gaap Depreciation
Depreciation
78039 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
33896 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
65868 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
66341 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
25687 usd
us-gaap Accretion Expense
AccretionExpense
2190620 usd
us-gaap Accretion Expense
AccretionExpense
6279 usd
us-gaap Share Based Compensation
ShareBasedCompensation
772851 usd
us-gaap Share Based Compensation
ShareBasedCompensation
516072 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
450000 usd
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
2656962 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
37434 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-25998 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
10942 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-55663 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-11450 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-18610 usd
VTRO Increase Decrease In Prepaid Project Costs
IncreaseDecreaseInPrepaidProjectCosts
112558 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-109510 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
177637 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
189970 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-66341 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-25687 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
240936 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-30748 usd
VTRO Increase Decrease In Accrued Liabilities Related Party
IncreaseDecreaseInAccruedLiabilitiesRelatedParty
-72059 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
73502 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
20418 usd
VTRO Increase Decrease In Accrued Interest Related Parties
IncreaseDecreaseInAccruedInterestRelatedParties
59475 usd
VTRO Increase Decrease In Accrued Interest Related Parties
IncreaseDecreaseInAccruedInterestRelatedParties
58969 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1728888 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1607374 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14270 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
486 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
29893 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-486 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-44163 usd
VTRO Proceeds From Issuance Of Series Senior Convertible Notes Payable Stock Settled
ProceedsFromIssuanceOfSeriesSeniorConvertibleNotesPayableStockSettled
3175000 usd
VTRO Proceeds From Note Subscription Payable
ProceedsFromNoteSubscriptionPayable
150000 usd
VTRO Proceeds From Issuance Of Convertible Notes Payable Stock Settled
ProceedsFromIssuanceOfConvertibleNotesPayableStockSettled
405000 usd
VTRO Proceeds From Issuance Of Series B Convertible Notes Payable Stock Settled
ProceedsFromIssuanceOfSeriesBConvertibleNotesPayableStockSettled
787600 usd
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
33364 usd
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
30881 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3291636 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1161719 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1562262 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-489818 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101754 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
741538 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1664016 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
251720 usd
us-gaap Interest Paid Net
InterestPaidNet
8331 usd
us-gaap Interest Paid Net
InterestPaidNet
10964 usd
VTRO Noncash Or Part Noncash Premium On Issuance Of Series Senior Notes Payable Stock Settled
NoncashOrPartNoncashPremiumOnIssuanceOfSeriesSeniorNotesPayableStockSettled
2645845 usd
VTRO Noncash Or Part Noncash Derivativewarrant Liability Series Senior Notes Payable
NoncashOrPartNoncashDerivativewarrantLiabilitySeriesSeniorNotesPayable
2890036 usd
VTRO Noncash Or Part Noncash Discount On Derivativewarrant Liability Series Senior Secured Notes Payable
NoncashOrPartNoncashDiscountOnDerivativewarrantLiabilitySeriesSeniorSecuredNotesPayable
5535882 usd
VTRO Noncash Or Part Noncash Premium On Issuance Of Series Notes Payable
NoncashOrPartNoncashPremiumOnIssuanceOfSeriesNotesPayable
397533 usd
VTRO Noncash Or Part Noncash Derivativewarrant Liability Series Notes Payable
NoncashOrPartNoncashDerivativewarrantLiabilitySeriesNotesPayable
641787 usd
VTRO Noncash Or Part Noncash Discount On Derivativewarrant Liability Series Notes Payable One
NoncashOrPartNoncashDiscountOnDerivativewarrantLiabilitySeriesNotesPayableOne
1039320 usd
VTRO Noncash Or Part Noncash Forgiveness Of Accrued Liabilities Related Party
NoncashOrPartNoncashForgivenessOfAccruedLiabilitiesRelatedParty
137953 usd
VTRO Noncash Or Part Noncash Deferred Offering Costs Recorded As Accounts Payable
NoncashOrPartNoncashDeferredOfferingCostsRecordedAsAccountsPayable
185016 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2246925 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1691474 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2246925 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1691474 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_z6heX5VG6y9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z404HfIdc6si">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage limits. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended April 30, 2024 and 2023, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20240430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ZamoraMember_zoIn6gSu6jr5" title="Concentration risk percentage">2</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20230430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ZamoraMember_zM27rOUZxLs2" title="Concentration risk percentage">3</span>% respectively, of the Company’s total revenues were derived from sales to an entity controlled by the Company’s former Chief Executive Officer and President, Dr. Jack Zamora (“Dr. Zamora”) (Note 10). Dr. Zamora is also a <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20240430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DrJackZamoraMember_zZUr4zVG6F5h" title="Concentration risk thresold percentage">30</span>% stockholder. During the six months ended April 30, 2024, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20240430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z2s0vmflYZxi" title="Concentration risk percentage">38</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20240430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zfNZBzMaA01d" title="Concentration risk percentage">25</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20240430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_z5Xsemg3LXq2" title="Concentration risk percentage">11</span>% of the Company’s total revenue was attributable to product sales to three customers. Also, during the six months ended April 30, 2023, one customer accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--CustomerOneMember_zZ0hj4WYkw83" title="Concentration risk percentage">45</span>% of the Company’s revenues. Other than the revenues derived through sales the customers referenced herein, no customer accounted for greater than <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--NoCustomerMember_z5kRCMc2kPrj" title="Concentration risk percentage"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20240430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--NoCustomerMember_z5p8kWRlEcZ5" title="Concentration risk percentage">10</span></span>% of the Company’s gross sales for the six months ended April 30, 2024 or 2023. In addition to the product revenue concentrations noted above, the Company recognized $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230201__20230430__srt--ProductOrServiceAxis__custom--ConsultingRevenueMember_zicY9SIJKGtb" title="Revenue">25,000</span> in consulting revenue from a single client during the three months ended April 30, 2023. This amount was <span id="xdx_901_ecustom--TotalRevenuePercentage_pid_dp_uPure_c20231101__20240430__srt--ProductOrServiceAxis__custom--ConsultingRevenueMember_zGyJc7iKOsDc" title="Total revenue percentage">4</span>% of the total revenue recognized for the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
2656962 usd
CY2023Q2 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zGFGOsfEzAv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zGtP2431LIq5">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
572937 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
307843 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
572937 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
307843 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
997147 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
651874 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
997147 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
651874 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
525387 usd
CY2024Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
685005 usd
CY2024Q2 VTRO Prepaid Project Costs
PrepaidProjectCosts
159618 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
525387 usd
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
525387 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
650000 usd
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
189970 usd
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
839970 usd
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
157105 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
119671 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
975 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
975 usd
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
11736 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
18856 usd
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
169958 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
151896 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
181694 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
170752 usd
CY2024Q2 VTRO Capitalized Patent Costs
CapitalizedPatentCosts
82811 usd
CY2023Q4 VTRO Capitalized Patent Costs
CapitalizedPatentCosts
82325 usd
us-gaap Net Income Loss
NetIncomeLoss
-7700000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5400000 usd
CY2024Q2 VTRO Working Capital Deficit
WorkingCapitalDeficit
8300000 usd
CY2024Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
3318927 usd
CY2024Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
12840 usd
CY2023Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
12840 usd
CY2024Q2 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
1046925 usd
CY2023Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
1046925 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1059765 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1059765 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
831136 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
739351 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
228629 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
320414 usd
CY2024Q2 us-gaap Depreciation
Depreciation
48241 usd
us-gaap Depreciation
Depreciation
91785 usd
CY2023Q2 us-gaap Depreciation
Depreciation
39675 usd
us-gaap Depreciation
Depreciation
78039 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1517926 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-884009 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
633917 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
63697 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
51416 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
51416 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
51416 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
51416 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
269361 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16948 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33896 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
32934 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
65868 usd
CY2024Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q2 us-gaap Area Of Land
AreaOfLand
2978
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
271396 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
271396 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
32734 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
66341 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
12674 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
25687 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
409900 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
476241 usd
CY2024Q2 VTRO Finance Property Plant And Equipment Gross
FinancePropertyPlantAndEquipmentGross
15500 usd
CY2023Q4 VTRO Finance Property Plant And Equipment Gross
FinancePropertyPlantAndEquipmentGross
33294 usd
CY2024Q2 VTRO Operating And Finance Lease Rightof Use Asset
OperatingAndFinanceLeaseRightofUseAsset
425400 usd
CY2023Q4 VTRO Operating And Finance Lease Rightof Use Asset
OperatingAndFinanceLeaseRightofUseAsset
509535 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124771 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
130150 usd
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
35269 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
61832 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
285129 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
346091 usd
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
10322 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
17123 usd
CY2024Q2 VTRO Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
455491 usd
CY2023Q4 VTRO Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
555196 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
109051 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
102517 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3996 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5800 usd
us-gaap Lease Cost
LeaseCost
113047 usd
us-gaap Lease Cost
LeaseCost
108317 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
81018 usd
CY2024Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
35270 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
163902 usd
CY2024Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
12803 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
166760 usd
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
5150 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
84609 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
67734 usd
CY2024Q2 VTRO Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
112890 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
676909 usd
CY2024Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
53223 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
267009 usd
CY2024Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
7632 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
409900 usd
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
45591 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2024Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M13D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M28D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1000 pure
CY2024Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0729 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1000 pure
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0749 pure
CY2023Q1 VTRO Noncash Or Part Noncash Premium On Issuance Of Notes Payable Stock Settled
NoncashOrPartNoncashPremiumOnIssuanceOfNotesPayableStockSettled
135000 usd
CY2023Q1 VTRO Noncash Or Part Noncash Premium On Issuance Of Notes Payable Stock Settled
NoncashOrPartNoncashPremiumOnIssuanceOfNotesPayableStockSettled
262533 usd
CY2023Q2 VTRO Noncash Or Part Noncash Premium On Issuance Of Notes Payable Stock Settled
NoncashOrPartNoncashPremiumOnIssuanceOfNotesPayableStockSettled
175000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
108248 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
51258 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
33364 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
30881 usd
CY2024Q2 VTRO Convertible Short Term Notes Payable Related Party
ConvertibleShortTermNotesPayableRelatedParty
480000 usd
CY2023Q4 VTRO Convertible Short Term Notes Payable Related Party
ConvertibleShortTermNotesPayableRelatedParty
480000 usd
CY2024Q2 VTRO Convertible Series Senior Secure Short Term Notes Payable
ConvertibleSeriesSeniorSecureShortTermNotesPayable
-3968750 usd
CY2024Q2 VTRO Convertible Series Senior Secure Short Term Notes Payable Discount
ConvertibleSeriesSeniorSecureShortTermNotesPayableDiscount
1537682 usd
CY2024Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
2911068 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
480000 usd
CY2024Q2 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
767288 usd
CY2023Q4 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
767288 usd
CY2024Q2 VTRO Unsecured Note Payable Related Party Noncurrent One
UnsecuredNotePayableRelatedPartyNoncurrentOne
1221958 usd
CY2023Q4 VTRO Unsecured Note Payable Related Party Noncurrent One
UnsecuredNotePayableRelatedPartyNoncurrentOne
1221958 usd
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
200000 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
200000 usd
CY2024Q2 VTRO Convertible Long Term Notes Payable Stock Settled
ConvertibleLongTermNotesPayableStockSettled
405000 usd
CY2023Q4 VTRO Convertible Long Term Notes Payable Stock Settled
ConvertibleLongTermNotesPayableStockSettled
405000 usd
CY2024Q2 VTRO Convertible Long Term Notes Payable Series Discount
ConvertibleLongTermNotesPayableSeriesDiscount
58317 usd
CY2023Q4 VTRO Convertible Long Term Notes Payable Series Discount
ConvertibleLongTermNotesPayableSeriesDiscount
64285 usd
CY2024Q2 VTRO Convertible Series B Long Term Notes Payable Stock Settled
ConvertibleSeriesBLongTermNotesPayableStockSettled
1312600 usd
CY2023Q4 VTRO Convertible Series B Long Term Notes Payable Stock Settled
ConvertibleSeriesBLongTermNotesPayableStockSettled
1312600 usd
CY2024Q2 VTRO Convertible Series B Long Term Notes Payable Series Discount
ConvertibleSeriesBLongTermNotesPayableSeriesDiscount
853035 usd
CY2023Q4 VTRO Convertible Series B Long Term Notes Payable Series Discount
ConvertibleSeriesBLongTermNotesPayableSeriesDiscount
891582 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2995494 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2950979 usd
CY2024Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
5906562 usd
CY2023Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
3430979 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
4448750 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1989246 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
200000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1717600 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
8355596 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
19230770 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4460535 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4460535 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4430535 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4430535 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1112923 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.84
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M20D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16889060 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1112923 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M20D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6895368 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
388367 usd
us-gaap Share Based Compensation
ShareBasedCompensation
772851 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
393510 usd
us-gaap Share Based Compensation
ShareBasedCompensation
516072 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
862410 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
831333 shares
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2726814 usd
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3506561 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
444454 shares
CY2023Q4 VTRO Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
20.56
CY2023 VTRO Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2
P1Y7M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
411377 shares
CY2024Q2 VTRO Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
21.27
VTRO Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2
P1Y3M3D
CY2024Q2 us-gaap Accrued Rent Current
AccruedRentCurrent
0 usd
CY2023Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
28222 usd
us-gaap Payments For Rent
PaymentsForRent
5645 usd

Files In Submission

Name View Source Status
0001493152-24-022030-index-headers.html Edgar Link pending
0001493152-24-022030-index.html Edgar Link pending
0001493152-24-022030.txt Edgar Link pending
0001493152-24-022030-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtro-20240430.xsd Edgar Link pending
vtro-20240430_cal.xml Edgar Link unprocessable
vtro-20240430_def.xml Edgar Link unprocessable
vtro-20240430_lab.xml Edgar Link unprocessable
vtro-20240430_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable